Please assess the completion status of the following clinical trial:

Trial Title: Japanese P III vs Voglibose and Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. Japanese patients with a diagnosis of type 2 diabetes mellitus. Antidiabetic therapy has to be stable for at least 10 weeks before Visit 1.~2. Glycosylated haemoglobin A1 (HbA1c) 7.0 - 10.0% at Visit 3 (beginning of the 2-week placebo run-in phase)~3. Age: \>= 20 and \<= 80~4. Body Mass Index (BMI) \<= 40 kg/m2~Exclusion criteria:~1. Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months before Visit 1~2. Impaired hepatic function~3. History of severe allergy/hypersensitivity~4. Treatment with anti-diabetic, anti obesity drugs, etc 3 months before Visit 1~5. Fasting blood glucose \>240 mg/dl (=13.3 mmol/L) at Visits 2 or 3

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- voglibose 0.2 mg three times a day (TID) (Type: ACTIVE_COMPARATOR): patient to receive a tablet containing 0.2 mg voglibose TID plus 2 placebo tablets matching BI 1356
- BI 1356 low dose (Type: EXPERIMENTAL): patient to receive a tablet containing BI 1356 and matching placebo plus 3 placebo tablets matching voglibose
- BI 1356 high dose (Type: EXPERIMENTAL): patient to receive 2 tablets containing BI 1356 plus 3 placebo tablets matching voglibose
- placebo (Type: PLACEBO_COMPARATOR): patient to receive 2 placebo tablets matching BI 1356 plus 3 placebo tablets matching voglibose

Based on this trial design, predict the completion outcome and termination type (if applicable).